<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887237</url>
  </required_header>
  <id_info>
    <org_study_id>TRIV</org_study_id>
    <nct_id>NCT00887237</nct_id>
  </id_info>
  <brief_title>Triple Site Ventricular Stimulation for Cardiac Resynchronization Therapy (CRT) Candidates</brief_title>
  <acronym>TRIV</acronym>
  <official_title>Triple Site Ventricular Stimulation for CRT Candidates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite technological progresses the rate of non-responders to cardiac resynchronization
      therapy (CRT) remains close to 30%. This inconsistent effect of CRT might be due to
      incomplete resynchronization as dyssynchrony can persist in 25% to 30% of patients during
      CRT.

      One might hypothesize that stimulating the ventricles at a single site is suboptimal and that
      stimulating multiple left ventricular (LV) or right ventricular (RV) sites may improve
      ventricular resynchronization and, consequently, its hemodynamic and clinical effects. First
      studies have suggested that 1 RV + 2 LV pacing sites configurations increased significantly
      dP/dt, pulse pressure, LV end-diastolic pressure, and is associated with more LV remodeling
      and better responder rate compared with pacing a single LV site. First studies with 2 RV+LV
      pacing sites configuration demonstrated increased dP/dt and cardiac output and a decrease of
      the cardiac dyssynchrony.

      The present pilot trial was designed to examine the 6-month safety of biventricular
      stimulation with 2 right ventricular (RV) and 1 left ventricular (LV) leads - main objective-
      and to assess its clinical benefit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of triple site CRT compared to conventional CRT</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of triple site CRT</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle remodeling</measure>
    <time_frame>At 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV ejection fraction</measure>
    <time_frame>At 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac dyssynchrony</measure>
    <time_frame>At 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status (clinical composite score and NYHA class)</measure>
    <time_frame>At 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity (6 minutes hall walk test distance)</measure>
    <time_frame>At 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-Type Natriuretic Peptide (BNP) level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>TRIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cardiac resynchronization with triple site ventricular stimulation (2 RV leads and 1 LV lead)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional cardiac resynchronization</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT with triple site ventricular stimulation</intervention_name>
    <description>CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)</description>
    <arm_group_label>TRIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional cardiac resynchronization</intervention_name>
    <description>Conventional cardiac resynchronization</description>
    <arm_group_label>BIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  &gt; 18 years old

          -  Cardiac resynchronization indication : New York Heart Association (NYHA) Class III/IV
             &amp; QRS width &gt; 120 ms milliseconds (ms) OR NYHA class II &amp; QRS width &gt; 150 ms

          -  Sinus rhythm

          -  First implant procedure

        Exclusion Criteria:

          -  Permanent ventricular tachycardia

          -  Permanent pacing indication for 3rd degree atrioventricular (AV) block

          -  Diagnosed or suspected acute myocarditis

          -  Less than 1 year life expectancy related to a non-cardiovascular disease

          -  Impossibility to perform follow-up in the investigative center

          -  Pregnant woman

          -  Patient which may not cooperate to study procedures as evaluated by investigator

          -  Legally protected adult patient or patient unable to give an informed consent

          -  Patient enrolled in an other clinical trial

          -  Patient which does not benefit from a social protection system

          -  Renal insufficiency

          -  Patient registered on a heart transplant waiting list

          -  Disease and/or health condition which may interfere with study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Anselme, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Rouen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Saint Louis</name>
      <address>
        <city>La Rochelle</city>
        <state>Ile de France</state>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvelles Cliniques Nantaises</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Bizet</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>Saint Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Cardiac resynchronization</keyword>
  <keyword>Triple site ventricular pacing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

